Novartis nixes another $600M buyout deal for Gamida Cell

John Carroll

 won't be pulling the trigger on a $ 600 million for Israel's after all. Elbit Imaging, the majority owner of a minority stakeholder in the stem player, says that the pharma giant has decided not to pursue its option on the company, but has signaled its willingness to push ahead with their collaboration.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS